This title appears in the Scientific Report :
2021
Please use the identifier:
http://hdl.handle.net/2128/27464 in citations.
Please use the identifier: http://dx.doi.org/10.1016/j.ejmech.2021.113214 in citations.
Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands
Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands
With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a che...
Saved in:
Personal Name(s): | Renk, Dana R. |
---|---|
Skraban, Marcel / Bier, Dirk / Schulze, Annette / Wabbals, Erika / Wedekind, Franziska / Neumaier, Felix / Neumaier, Bernd / Holschbach, Marcus (Corresponding author) | |
Contributing Institute: |
Nuklearchemie; INM-5 Molekulare Organisation des Gehirns; INM-2 |
Published in: | European Journal of Medicinal Chemistry European journal of medicinal chemistry, 214 214 (2021 2021) S. 113214 113214 |
Imprint: |
Amsterdam [u.a.]
Elsevier71544
2021
2021-03-01 |
DOI: |
10.1016/j.ejmech.2021.113214 |
Document Type: |
Journal Article |
Research Program: |
Decoding Brain Organization and Dysfunction |
Link: |
Restricted Published on 2020-01-30. Available in OpenAccess from 2022-01-30. |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.1016/j.ejmech.2021.113214 in citations.
LEADER | 13362nam a2201681 a 4500 | ||
---|---|---|---|
001 | 891313 | ||
005 | 20230217124544.0 | ||
024 | 7 | |a 10.1016/j.ejmech.2021.113214 |2 doi | |
024 | 7 | |a 0009-4374 |2 ISSN | |
024 | 7 | |a 0223-5234 |2 ISSN | |
024 | 7 | |a 1768-3254 |2 ISSN | |
024 | 7 | |a 2128/27464 |2 Handle | |
024 | 7 | |a 33548636 |2 pmid | |
024 | 7 | |a WOS:000629633800015 |2 WOS | |
037 | |a FZJ-2021-01420 | ||
041 | |a English | ||
082 | |a 610 | ||
100 | 1 | |a Renk, Dana R. |0 P:(DE-Juel1)174096 |b 0 | |
245 | |a Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands | ||
260 | |a Amsterdam [u.a.] |c 2021 |b Elsevier71544 | ||
264 | 1 | |3 print |2 Crossref |b Elsevier BV |c 2021-03-01 | |
520 | |a With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer. | ||
542 | |i 2021-03-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ | ||
542 | |i 2021-03-01 |2 Crossref |u https://doi.org/10.15223/policy-017 | ||
542 | |i 2021-03-01 |2 Crossref |u https://doi.org/10.15223/policy-037 | ||
542 | |i 2021-03-01 |2 Crossref |u https://doi.org/10.15223/policy-012 | ||
542 | |i 2021-03-01 |2 Crossref |u https://doi.org/10.15223/policy-029 | ||
542 | |i 2021-03-01 |2 Crossref |u https://doi.org/10.15223/policy-004 | ||
588 | |a Dataset connected to CrossRef | ||
700 | 1 | |a Skraban, Marcel |0 P:(DE-Juel1)157984 |b 1 | |
700 | 1 | |a Bier, Dirk |0 P:(DE-Juel1)131810 |b 2 |u fzj | |
700 | 1 | |a Schulze, Annette |0 P:(DE-Juel1)131847 |b 3 |u fzj | |
700 | 1 | |a Wabbals, Erika |0 P:(DE-Juel1)131852 |b 4 | |
700 | 1 | |a Wedekind, Franziska |0 P:(DE-Juel1)131711 |b 5 |u fzj | |
700 | 1 | |a Neumaier, Felix |0 P:(DE-Juel1)175142 |b 6 | |
700 | 1 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 7 |u fzj | |
700 | 1 | |a Holschbach, Marcus |0 P:(DE-Juel1)131824 |b 8 |e Corresponding author | |
773 | 1 | 8 | |a 10.1016/j.ejmech.2021.113214 |b Elsevier BV |d 2021-03-01 |p 113214 |3 journal-article |2 Crossref |t European Journal of Medicinal Chemistry |v 214 |y 2021 |x 0223-5234 |
773 | |a 10.1016/j.ejmech.2021.113214 |g Vol. 214, p. 113214 - |0 PERI:(DE-600)2005170-0 |p 113214 |t European journal of medicinal chemistry |v 214 |y 2021 |x 0223-5234 | ||
856 | 4 | |u http://juser.fz-juelich.de/record/891313/files/1-s2.0-S0223523421000635-main.pdf |y Restricted | |
856 | 4 | |u http://juser.fz-juelich.de/record/891313/files/EJMECH-D-20-03196_For_Central_Library.pdf |y Published on 2020-01-30. Available in OpenAccess from 2022-01-30. | |
909 | C | O | |o oai:juser.fz-juelich.de:891313 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)174096 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131810 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131847 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131852 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131711 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)175142 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)166419 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131824 | |
913 | 1 | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |x 0 | |
913 | 0 | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-500 |4 G:(DE-HGF)POF |v Neuroimaging |x 0 | |
914 | 1 | |y 2021 | |
915 | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search | ||
915 | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC | ||
915 | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID | ||
915 | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J MED CHEM : 2015 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection | ||
915 | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index | ||
915 | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded | ||
915 | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID | ||
915 | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List | ||
980 | |a journal | ||
980 | |a VDB | ||
980 | |a I:(DE-Juel1)INM-5-20090406 | ||
980 | |a I:(DE-Juel1)INM-2-20090406 | ||
980 | |a UNRESTRICTED | ||
980 | 1 | |a FullTexts | |
999 | C | 5 | |1 Fredholm |y 2001 |2 Crossref |o Fredholm 2001 |
999 | C | 5 | |a 10.1523/JNEUROSCI.5066-06.2007 |9 -- missing cx lookup -- |1 Elmenhorst |p 2410 - |2 Crossref |t J. Neurosci. |v 27 |y 2007 |
999 | C | 5 | |a 10.3109/07853899908998788 |9 -- missing cx lookup -- |1 Porkka-Heiskanen |p 125 - |2 Crossref |t Ann. Med. |v 31 |y 1999 |
999 | C | 5 | |a 10.1016/S0306-4522(96)00640-9 |9 -- missing cx lookup -- |1 Portas |p 225 - |2 Crossref |t Neuroscience |v 79 |y 1997 |
999 | C | 5 | |a 10.1016/B978-0-12-801022-8.00012-X |p 257 - |1 Chen |y 2014 |2 Crossref |9 -- missing cx lookup -- |
999 | C | 5 | |a 10.2741/2870 |9 -- missing cx lookup -- |1 Takahashi |p 2614 - |2 Crossref |t Front. Biosci. |v 13 |y 2008 |
999 | C | 5 | |a 10.1016/0033-0620(81)90030-X |9 -- missing cx lookup -- |1 Berne |p 243 - |2 Crossref |t Prog. Cardiovasc. Dis. |v 24 |y 1981 |
999 | C | 5 | |1 Dirnagl |y 1994 |2 Crossref |o Dirnagl 1994 |
999 | C | 5 | |a 10.1016/B978-0-12-801022-8.00003-9 |p 71 - |1 Jenner |y 2014 |2 Crossref |9 -- missing cx lookup -- |
999 | C | 5 | |a 10.1111/j.1460-9568.2009.06897.x |9 -- missing cx lookup -- |1 D’Alimonte |p 1023 - |2 Crossref |t Eur. J. Neurosci. |v 30 |y 2009 |
999 | C | 5 | |a 10.1016/j.jpsychires.2013.12.013 |9 -- missing cx lookup -- |1 Villar-Menéndez |p 49 - |2 Crossref |t J. Psychiatr. Res. |v 51 |y 2014 |
999 | C | 5 | |a 10.1038/sj.bjp.0704240 |9 -- missing cx lookup -- |1 El Yacoubi |p 68 - |2 Crossref |t Br. J. Pharmacol. |v 134 |y 2001 |
999 | C | 5 | |a 10.1155/2017/6975841 |9 -- missing cx lookup -- |1 Vuorimaa |p 1 - |2 Crossref |t Contrast Media Mol. Imaging |y 2017 |
999 | C | 5 | |a 10.1002/med.21432 |9 -- missing cx lookup -- |1 van Waarde |p 5 - |2 Crossref |t Med. Res. Rev. |v 38 |y 2018 |
999 | C | 5 | |a 10.1016/0306-4522(91)90038-P |9 -- missing cx lookup -- |1 Martinez-Mir |p 697 - |2 Crossref |t Neuroscience |v 42 |y 1991 |
999 | C | 5 | |a 10.1385/JMN:26:2-3:209 |9 -- missing cx lookup -- |1 Fuxe |p 209 - |2 Crossref |t J. Mol. Neurosci. |v 26 |y 2005 |
999 | C | 5 | |a 10.2967/jnumed.114.152546 |9 -- missing cx lookup -- |1 Barret |p 586 - |2 Crossref |t J. Nucl. Med. |v 56 |y 2015 |
999 | C | 5 | |a 10.1016/S1474-4422(11)70012-6 |9 -- missing cx lookup -- |1 Hauser |p 221 - |2 Crossref |t Lancet Neurol. |v 10 |y 2011 |
999 | C | 5 | |a 10.1007/s40265-013-0066-7 |9 -- missing cx lookup -- |1 Dungo |p 875 - |2 Crossref |t Drugs |v 73 |y 2013 |
999 | C | 5 | |a 10.3390/ph13090237 |9 -- missing cx lookup -- |1 Zhang |p 237 - |2 Crossref |t Pharmaceuticals |v 13 |y 2020 |
999 | C | 5 | |a 10.1021/acs.jmedchem.0c00237 |9 -- missing cx lookup -- |1 Yu |p 12196 - |2 Crossref |t J. Med. Chem. |v 63 |y 2020 |
999 | C | 5 | |a 10.1021/jm4011669 |9 -- missing cx lookup -- |1 de Lera Ruiz |p 3623 - |2 Crossref |t J. Med. Chem. |v 57 |y 2014 |
999 | C | 5 | |1 Shah |y 2010 |2 Crossref |o Shah 2010 |
999 | C | 5 | |a 10.1021/jm9911480 |9 -- missing cx lookup -- |1 Sauer |p 440 - |2 Crossref |t J. Med. Chem. |v 43 |y 2000 |
999 | C | 5 | |a 10.1212/01.WNL.0000095219.22086.31 |9 -- missing cx lookup -- |1 Kase |p 97 - |2 Crossref |t Neurology |v 61 |y 2003 |
999 | C | 5 | |1 Williams |y 1987 |2 Crossref |o Williams 1987 |
999 | C | 5 | |a 10.1016/S0960-894X(01)80279-1 |9 -- missing cx lookup -- |1 Baraldi |p 2539 - |2 Crossref |t Med. Chem. Lett. |v 4 |y 1994 |
999 | C | 5 | |a 10.1039/p19950000801 |9 -- missing cx lookup -- |1 Caulkett |p 801 - |2 Crossref |t J. Chem. Soc., Perkin Trans. |v 1 |y 1995 |
999 | C | 5 | |1 Vu |y 2005 |2 Crossref |o Vu 2005 |
999 | C | 5 | |2 Crossref |u A. Flohr, J.-L. Moreau, S.M. Poli, C. Riemer, L. Steward, 4-Hydroxy-4-methyl-piperidine-1-carboxylic Acid (4-Methoxy-7-Morpholin-4-Yl-Benzothiazol-2-Yl)-Amide, US Patent US 7368446 B2 (2008).. |
999 | C | 5 | |1 Yuan |y 2017 |2 Crossref |o Yuan 2017 |
999 | C | 5 | |a 10.1021/acs.jmedchem.6b01584 |9 -- missing cx lookup -- |1 Basu |p 681 - |2 Crossref |t J. Med. Chem. |v 60 |y 2017 |
999 | C | 5 | |a 10.1021/jm9705465 |9 -- missing cx lookup -- |1 Holschbach |p 555 - |2 Crossref |t J. Med. Chem. |v 41 |y 1998 |
999 | C | 5 | |a 10.1021/op700074k |9 -- missing cx lookup -- |1 Zhang |p 861 - |2 Crossref |t Org. Process Res. Dev. |v 11 |y 2007 |
999 | C | 5 | |2 Crossref |u P. Spurr, Cyclization Process for Substituted Benzothiazol Derivatives, US Patent US 7081761 B2 (2006).. |
999 | C | 5 | |a 10.1021/jacs.5b06307 |9 -- missing cx lookup -- |1 Nielsen |p 9571 - |2 Crossref |t J. Am. Chem. Soc. |v 137 |y 2015 |
999 | C | 5 | |a 10.1021/jacs.7b07891 |9 -- missing cx lookup -- |1 Parisi |p 13648 - |2 Crossref |t J. Am. Chem. Soc. |v 139 |y 2017 |
999 | C | 5 | |a 10.1021/ja00713a071 |9 -- missing cx lookup -- |1 Rathke |p 3222 - |2 Crossref |t J. Am. Chem. Soc. |v 92 |y 1970 |
999 | C | 5 | |a 10.1055/s-1997-1335 |9 -- missing cx lookup -- |1 Thavonekham |p 1189 - |2 Crossref |t Synthesis |v 1997 |y 1997 |
999 | C | 5 | |a 10.1021/ja01084a034 |9 -- missing cx lookup -- |1 Corey |p 1353 - |2 Crossref |t J. Am. Chem. Soc. |v 87 |y 1965 |
999 | C | 5 | |a 10.1021/ja00230a045 |9 -- missing cx lookup -- |1 Gao |p 7538 - |2 Crossref |t J. Am. Chem. Soc. |v 110 |y 1968 |
999 | C | 5 | |1 Armarego |y 2009 |2 Crossref |o Armarego 2009 |
999 | C | 5 | |2 Crossref |u E. Verner, K.A. Brameld, Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors, US Patent WO 2015120049 A1 (2015).. |
999 | C | 5 | |2 Crossref |u J.J. Crawford, J. Drobnick, L.J. Zard, W. Lee, C. Ndubaku, J. Rudolph, Pyrimidine-pyridinone Serine/threonine Kinase Inhibitors, US Patent WO 2015011252 A1 (2015).. |
999 | C | 5 | |a 10.1021/ja9806128 |9 -- missing cx lookup -- |1 Evans |p 5921 - |2 Crossref |t J. Am. Chem. Soc. |v 120 |y 1998 |
999 | C | 5 | |a 10.1016/S0040-4039(01)80274-4 |9 -- missing cx lookup -- |1 Kim |p 655 - |2 Crossref |t Tetrahedron Lett. |v 30 |y 1989 |
999 | C | 5 | |a 10.1111/j.1471-4159.2006.03666.x |9 -- missing cx lookup -- |1 Wachten |p 1580 - |2 Crossref |t J. Neurochem. |v 96 |y 2006 |
999 | C | 5 | |1 Chen |y 1987 |2 Crossref |o Chen 1987 |
999 | C | 5 | |a 10.1007/BF00518781 |9 -- missing cx lookup -- |1 Lohse |p 69 - |2 Crossref |t Naunyn-Schmiedeberg’s Arch. Pharmacol. |v 326 |y 1984 |
999 | C | 5 | |a 10.1515/bchm2.1979.360.2.1657 |9 -- missing cx lookup -- |1 Neuhoff |p 1657 - |2 Crossref |t Z. Physiol. Chem. |v 360 |y 1979 |
999 | C | 5 | |a 10.1089/adt.2020.991 |9 -- missing cx lookup -- |1 Bier |p 328 - |2 Crossref |t Assay Drug Dev. Technol. |v 18 |y 2020 |
536 | |a Decoding Brain Organization and Dysfunction |0 G:(DE-HGF)POF4-525 |c POF4-525 |f POF IV |x 0 | ||
336 | |a ARTICLE |2 BibTeX | ||
336 | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1654069056_6248 |2 PUB:(DE-HGF) | ||
336 | |a Output Types/Journal article |2 DataCite | ||
336 | |a article |2 DRIVER | ||
336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
336 | |a JOURNAL_ARTICLE |2 ORCID | ||
920 | |k Nuklearchemie; INM-5 |0 I:(DE-Juel1)INM-5-20090406 |l Nuklearchemie |x 0 | ||
920 | |k Molekulare Organisation des Gehirns; INM-2 |0 I:(DE-Juel1)INM-2-20090406 |l Molekulare Organisation des Gehirns |x 1 | ||
991 | |a Holschbach, Marcus |0 P:(DE-Juel1)131824 |b 8 |e Corresponding author | ||
991 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 7 |u fzj | ||
991 | |a Neumaier, Felix |0 P:(DE-Juel1)175142 |b 6 | ||
990 | |a Renk, Dana Rebecca |0 P:(DE-Juel1)174096 |b 0 | ||
991 | |a Wedekind, Franziska |0 P:(DE-Juel1)131711 |b 5 |u fzj | ||
991 | |a Wabbals, Erika |0 P:(DE-Juel1)131852 |b 4 | ||
991 | |a Schulze, Annette |0 P:(DE-Juel1)131847 |b 3 |u fzj | ||
991 | |a Bier, Dirk |0 P:(DE-Juel1)131810 |b 2 |u fzj | ||
991 | |a Skraban, Marcel |0 P:(DE-Juel1)157984 |b 1 |